SG11201912827TA - 7-substituted pyrrolotriazine compounds or pharmaceutically acceptable salts thereof, and preparation methods and uses thereof - Google Patents

7-substituted pyrrolotriazine compounds or pharmaceutically acceptable salts thereof, and preparation methods and uses thereof

Info

Publication number
SG11201912827TA
SG11201912827TA SG11201912827TA SG11201912827TA SG11201912827TA SG 11201912827T A SG11201912827T A SG 11201912827TA SG 11201912827T A SG11201912827T A SG 11201912827TA SG 11201912827T A SG11201912827T A SG 11201912827TA SG 11201912827T A SG11201912827T A SG 11201912827TA
Authority
SG
Singapore
Prior art keywords
pharmaceutically acceptable
acceptable salts
preparation methods
pyrrolotriazine compounds
substituted pyrrolotriazine
Prior art date
Application number
SG11201912827TA
Inventor
Chunhao Yang
Linghua Meng
Haoyue Xiang
Jing Li
Xi Zhang
Xiang Wang
Cun Tan
Qian He
Jian Ding
Yi Chen
Original Assignee
Shanghai Institute Of Materia Medica Chinese Academy Of Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Institute Of Materia Medica Chinese Academy Of Sciences filed Critical Shanghai Institute Of Materia Medica Chinese Academy Of Sciences
Publication of SG11201912827TA publication Critical patent/SG11201912827TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
SG11201912827TA 2017-06-23 2018-06-22 7-substituted pyrrolotriazine compounds or pharmaceutically acceptable salts thereof, and preparation methods and uses thereof SG11201912827TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710493411.2A CN109111447A (en) 2017-06-23 2017-06-23 7- substituted azole triazin compounds or its pharmaceutically available salt, and its preparation method and application
PCT/CN2018/092419 WO2018233684A1 (en) 2017-06-23 2018-06-22 7-site substituted pyrrole triazine compounds or pharmaceutically acceptable salts thereof, and preparation method therefor and uses thereof

Publications (1)

Publication Number Publication Date
SG11201912827TA true SG11201912827TA (en) 2020-01-30

Family

ID=64733772

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201912827TA SG11201912827TA (en) 2017-06-23 2018-06-22 7-substituted pyrrolotriazine compounds or pharmaceutically acceptable salts thereof, and preparation methods and uses thereof

Country Status (13)

Country Link
US (1) US11214572B2 (en)
EP (1) EP3643717B1 (en)
JP (1) JP6852199B2 (en)
KR (1) KR102413943B1 (en)
CN (2) CN109111447A (en)
AU (1) AU2018287971B9 (en)
BR (1) BR112019027545A2 (en)
CA (1) CA3068114C (en)
ES (1) ES2887629T3 (en)
PT (1) PT3643717T (en)
RU (1) RU2745548C1 (en)
SG (1) SG11201912827TA (en)
WO (1) WO2018233684A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3154079A1 (en) * 2019-09-19 2021-03-25 Totus Medicines Inc. Therapeutic conjugates
CN111909153B (en) * 2020-04-16 2021-11-19 山东鲁西药业有限公司 Synthesis process of 7-iodopyrrolo [2,1-F ] [1,2,4] triazin-4-amine

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005245875C1 (en) 2004-05-13 2017-08-31 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
EP2435438A1 (en) 2009-05-27 2012-04-04 Genentech, Inc. Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
KR20140036269A (en) * 2011-07-01 2014-03-25 바이엘 인텔렉쳐 프로퍼티 게엠베하 Hydroxymethylaryl-substituted pyrrolotriazines as alk1 inhibitors
TW201350474A (en) 2012-03-06 2013-12-16 Boehringer Ingelheim Int Benzodioxane inhibitors of leukotriene production
CN103450204B (en) * 2012-05-31 2016-08-17 中国科学院上海药物研究所 Pyrroles [2,1-f] [1,2,4] triazin compound, Preparation Method And The Use
CN102675323B (en) 2012-06-01 2014-04-09 南京药石药物研发有限公司 Pyrrole-[2, 1-f] [1, 2 and 4] triazine derivative and antitumor effect thereof
JOP20130273B1 (en) 2012-09-11 2021-08-17 Genzyme Corp Glucosylceramide synthase inhibitors
JP6441910B2 (en) * 2013-09-30 2018-12-19 シャンハイ インリ ファーマシューティカル カンパニー リミティド Fused pyrimidine compounds, intermediates, methods for their preparation, compositions and uses
JP6858252B2 (en) * 2016-06-25 2021-04-14 スーチョウ キンター ファーマシューティカルズ インコーポレイテッド Mechanism of rapamycin signaling pathway inhibitors Targets and their therapeutic applications

Also Published As

Publication number Publication date
EP3643717A1 (en) 2020-04-29
PT3643717T (en) 2021-08-31
CA3068114A1 (en) 2018-12-27
AU2018287971B9 (en) 2021-02-11
JP6852199B2 (en) 2021-03-31
US11214572B2 (en) 2022-01-04
CN110869371B (en) 2022-04-15
RU2745548C1 (en) 2021-03-26
US20200157110A1 (en) 2020-05-21
KR102413943B1 (en) 2022-06-27
AU2018287971B2 (en) 2020-12-24
CN109111447A (en) 2019-01-01
KR20200015786A (en) 2020-02-12
AU2018287971A8 (en) 2021-02-04
BR112019027545A2 (en) 2020-07-07
AU2018287971A1 (en) 2020-02-13
WO2018233684A1 (en) 2018-12-27
AU2018287971B8 (en) 2021-02-04
EP3643717A4 (en) 2020-04-29
ES2887629T3 (en) 2021-12-23
JP2020527541A (en) 2020-09-10
CA3068114C (en) 2022-05-10
EP3643717B1 (en) 2021-06-02
CN110869371A (en) 2020-03-06

Similar Documents

Publication Publication Date Title
IL288104A (en) Heterocyclic compounds, preparation methods and uses thereof
EP3534903A4 (en) Substituted pyridinone-containing tricyclic compounds, and methods using same
EP3444228A4 (en) Multilayer body, preparation method therefor and use thereof
EP3559000A4 (en) Benzimidazole derivatives, preparation methods and uses theirof
EP3096763A4 (en) Novel process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof
EP3452481A4 (en) SUBSTITUTED IMIDAZO[1,2-b
IL272446A (en) Substituted penta- fused hexa-heterocyclic compounds, preparation method therefor, drug combination and use thereof
EP3621613A4 (en) Aminopyridine compounds and methods for the preparation and use thereof
IL260366B (en) Quinolin-2-one derivatives, their preparation and use
EP3569602A4 (en) Imidazopyrazine compound, preparation method therefor and use thereof
EP3115361A4 (en) Heterocyclic compounds, and preparation method and use thereof
EP3144292A4 (en) 2,3,4,6-tetra-substituted benzene-1,5-diamine derivatives, preparation method therefor and medicinal use thereof
EP3327014A4 (en) Egfr inhibitor and pharmaceutically acceptable salt and polymorph thereof, and use thereof
SG11202007521PA (en) Urea-substituted aromatic ring-linked dioxazoline compound, preparation method therefor, and uses thereof
EP3705478A4 (en) Triazine compound and pharmaceutically acceptable salt thereof
EP3173089A4 (en) Brain function improving agent, and prophylactic or therapeutic agent for cognitive dysfunction
IL263172A (en) Tricyclic heterocyclic derivatives, their preparation and use
EP3699179A4 (en) Pyrazolyl-containing tricyclic derivative, preparation method therefor and use thereof
GB201506116D0 (en) Kit and combination therapy for nausea and vomiting
EP3541931A4 (en) Fractal combination therapy
SG11201912827TA (en) 7-substituted pyrrolotriazine compounds or pharmaceutically acceptable salts thereof, and preparation methods and uses thereof
ZA202004349B (en) Fluoralkenyl compounds, process for preparation and use thereof
HK1251476A1 (en) Aminothiolester compounds or pharmaceutically acceptable salts thereof, for use in the treatment of cancer
EP3241823A4 (en) Pyrrole amide compound, preparation method therefor, and use thereof
EP3150576A4 (en) Substituted acetohydrazide derivatives, preparation method therefor and use